{"id":20990,"date":"2025-01-08T19:24:25","date_gmt":"2025-01-08T11:24:25","guid":{"rendered":"https:\/\/flcube.com\/?p=20990"},"modified":"2025-01-08T19:24:27","modified_gmt":"2025-01-08T11:24:27","slug":"inceptor-bio-and-grit-biotechnology-partner-to-advance-car-t-therapy-ib-t101-for-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=20990","title":{"rendered":"Inceptor Bio and GRIT Biotechnology Partner to Advance CAR-T Therapy IB-T101 for Solid Tumors"},"content":{"rendered":"\n

US-based Inceptor Bio has entered into a partnership with Chinese firm GRIT Biotechnology to advance the potential best-in-class chimeric antigen receptor (CAR)-T therapy, IB-T101, for the treatment of solid tumors. This collaboration combines the expertise of two cell therapy specialists to enhance the development and commercialization of innovative cancer treatments.<\/p>\n\n\n\n

Program Details and Technology<\/strong>
IB-T101 is Inceptor Bio\u2019s autologous CD70 CAR-T program, which utilizes the proprietary OUTLAST platform to reprogram T cells for superior stemness, durability, and effector function in the hostile tumor microenvironment. The program specifically targets clear cell Renal Cell Carcinoma (ccRCC), a cancer with significant unmet medical need and over 300,000 new cases annually worldwide.<\/p>\n\n\n\n

Agreement Terms<\/strong>
Under the terms of the agreement, GRIT Biotechnology will be responsible for the development, manufacturing, and commercialization of IB-T101 in China. Inceptor Bio is eligible to receive an undisclosed amount of milestone payments and royalties. Clinical data from the collaboration is expected to support regulatory filing and development in other territories.<\/p>\n\n\n\n

Significance of the Partnership<\/strong>
This strategic collaboration underscores the commitment of both Inceptor Bio and GRIT Biotechnology to advancing cutting-edge CAR-T therapies. By leveraging their combined expertise, the companies aim to accelerate the development of IB-T101 and bring innovative treatment options to patients with solid tumors, particularly those suffering from ccRCC.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

US-based Inceptor Bio has entered into a partnership with Chinese firm GRIT Biotechnology to advance…<\/p>\n","protected":false},"author":1,"featured_media":20994,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,21,542,3088],"class_list":["post-20990","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cancer","tag-car-t","tag-grit-biotechnology","tag-inceptor-bio"],"yoast_head":"\nInceptor Bio and GRIT Biotechnology Partner to Advance CAR-T Therapy IB-T101 for Solid Tumors - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based Inceptor Bio has entered into a partnership with Chinese firm GRIT Biotechnology to advance the potential best-in-class chimeric antigen receptor (CAR)-T therapy, IB-T101, for the treatment of solid tumors. This collaboration combines the expertise of two cell therapy specialists to enhance the development and commercialization of innovative cancer treatments.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=20990\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Inceptor Bio and GRIT Biotechnology Partner to Advance CAR-T Therapy IB-T101 for Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"US-based Inceptor Bio has entered into a partnership with Chinese firm GRIT Biotechnology to advance the potential best-in-class chimeric antigen receptor (CAR)-T therapy, IB-T101, for the treatment of solid tumors. This collaboration combines the expertise of two cell therapy specialists to enhance the development and commercialization of innovative cancer treatments.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=20990\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-08T11:24:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-08T11:24:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0821.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20990#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20990\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Inceptor Bio and GRIT Biotechnology Partner to Advance CAR-T Therapy IB-T101 for Solid Tumors\",\"datePublished\":\"2025-01-08T11:24:25+00:00\",\"dateModified\":\"2025-01-08T11:24:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20990\"},\"wordCount\":231,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20990#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0821.png\",\"keywords\":[\"Cancer\",\"CAR-T\",\"GRIT Biotechnology\",\"Inceptor Bio\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20990#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20990\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=20990\",\"name\":\"Inceptor Bio and GRIT Biotechnology Partner to Advance CAR-T Therapy IB-T101 for Solid Tumors - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20990#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20990#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0821.png\",\"datePublished\":\"2025-01-08T11:24:25+00:00\",\"dateModified\":\"2025-01-08T11:24:27+00:00\",\"description\":\"US-based Inceptor Bio has entered into a partnership with Chinese firm GRIT Biotechnology to advance the potential best-in-class chimeric antigen receptor (CAR)-T therapy, IB-T101, for the treatment of solid tumors. This collaboration combines the expertise of two cell therapy specialists to enhance the development and commercialization of innovative cancer treatments.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20990#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20990\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20990#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0821.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0821.png\",\"width\":1080,\"height\":600,\"caption\":\"Inceptor Bio and GRIT Biotechnology Partner to Advance CAR-T Therapy IB-T101 for Solid Tumors\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20990#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Inceptor Bio and GRIT Biotechnology Partner to Advance CAR-T Therapy IB-T101 for Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Inceptor Bio and GRIT Biotechnology Partner to Advance CAR-T Therapy IB-T101 for Solid Tumors - Insight, China's Pharmaceutical Industry","description":"US-based Inceptor Bio has entered into a partnership with Chinese firm GRIT Biotechnology to advance the potential best-in-class chimeric antigen receptor (CAR)-T therapy, IB-T101, for the treatment of solid tumors. This collaboration combines the expertise of two cell therapy specialists to enhance the development and commercialization of innovative cancer treatments.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=20990","og_locale":"en_US","og_type":"article","og_title":"Inceptor Bio and GRIT Biotechnology Partner to Advance CAR-T Therapy IB-T101 for Solid Tumors","og_description":"US-based Inceptor Bio has entered into a partnership with Chinese firm GRIT Biotechnology to advance the potential best-in-class chimeric antigen receptor (CAR)-T therapy, IB-T101, for the treatment of solid tumors. This collaboration combines the expertise of two cell therapy specialists to enhance the development and commercialization of innovative cancer treatments.","og_url":"https:\/\/flcube.com\/?p=20990","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-08T11:24:25+00:00","article_modified_time":"2025-01-08T11:24:27+00:00","og_image":[{"width":1080,"height":600,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0821.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=20990#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=20990"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Inceptor Bio and GRIT Biotechnology Partner to Advance CAR-T Therapy IB-T101 for Solid Tumors","datePublished":"2025-01-08T11:24:25+00:00","dateModified":"2025-01-08T11:24:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=20990"},"wordCount":231,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=20990#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0821.png","keywords":["Cancer","CAR-T","GRIT Biotechnology","Inceptor Bio"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=20990#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=20990","url":"https:\/\/flcube.com\/?p=20990","name":"Inceptor Bio and GRIT Biotechnology Partner to Advance CAR-T Therapy IB-T101 for Solid Tumors - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=20990#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=20990#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0821.png","datePublished":"2025-01-08T11:24:25+00:00","dateModified":"2025-01-08T11:24:27+00:00","description":"US-based Inceptor Bio has entered into a partnership with Chinese firm GRIT Biotechnology to advance the potential best-in-class chimeric antigen receptor (CAR)-T therapy, IB-T101, for the treatment of solid tumors. This collaboration combines the expertise of two cell therapy specialists to enhance the development and commercialization of innovative cancer treatments.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=20990#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=20990"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=20990#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0821.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0821.png","width":1080,"height":600,"caption":"Inceptor Bio and GRIT Biotechnology Partner to Advance CAR-T Therapy IB-T101 for Solid Tumors"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=20990#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Inceptor Bio and GRIT Biotechnology Partner to Advance CAR-T Therapy IB-T101 for Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0821.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20990","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20990"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20990\/revisions"}],"predecessor-version":[{"id":20995,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20990\/revisions\/20995"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/20994"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20990"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20990"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20990"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}